Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- F-1/A Registration statement (foreign)
- 3.1 Form of Amended and Restated Articles of Association of NLS Pharmaceutics LTD.
- 10.20 Amendment Number 2 to Convertible Loan Agreement Dated February 21, 2020 Between NLS Pharmaceutics LTD. and Alexander Zwyer
- 10.21 Amendment Number 3 to Convertible Loan Agreement Dated February 21, 2020 Between NLS Pharmaceutics LTD. and Alexander Zwyer
- 10.22 Bridgeloan Agreement Between NLS Pharmaceutics LTD. and Magnetic Rock Investment Ag
- 10.23 Amendment to Bridge Loan Agreement Between NLS Pharmaceutics LTD. and Magnetic Rock Investment Ag
- 10.24 Form of Amendment to Convertible Loan Agreement Between NLS Pharmaceutics LTD. and Certain Lenders
- 10.25 Form of Addendum Number 3 to Promissory Note Dated January 2019 Between Certain Investors and the Company
- 10.26 Addendum Number 3 to Credit Facility Dated August 31, 2015 Between NLS Pharma Ag and the Lenders Named Therein
- 10.27 Addendum Number 3 to Credit Facility Dated August 31, 2015 Between NLS-1 Pharma Ag and the Lenders Named Therein
- 10.28 Addendum Number 2 to Convertible Promissory Note Dated January 18, 2019 Between Magnetic Rock Investment Ag and the Company
- 23.1 Consent of Marcum LLP
- 99.1 Consent of Stig Lokke Pedersen
- 99.2 Consent of Myoung-ok Kwon
Associated filings
- 4 Oct 21 EFFECT Notice of effectiveness
- 30 Sep 21 POS AM Prospectus update (post-effective amendment)
- 7 Jun 21 EFFECT Notice of effectiveness
- 27 May 21 POS AM Prospectus update (post-effective amendment)
- 2 Feb 21 POS EX Additional exhibits for listing
- 1 Feb 21 424B4 Prospectus supplement with pricing info
- 29 Jan 21 EFFECT Notice of effectiveness
- 20 Jan 21 F-1/A Registration statement (foreign) (amended)
- 17 Nov 20 F-1/A Registration statement (foreign) (amended)
- 13 Nov 20 F-1/A Registration statement (foreign) (amended)
-
16 Oct 20 F-1/A Registration statement (foreign) (amended)
- 31 Aug 20 F-1/A Registration statement (foreign) (amended)
- 28 Feb 20 F-1 Registration statement (foreign)
NLSP similar filings
Filing view
External links
Exhibit 99.1
CONSENT OF STIG LØKKE PEDERSEN TO BE NAMED AS A DIRECTOR NOMINEE
The undersigned hereby consents to being named in the Registration Statement on Form F-1/A (Registration No. 333-236797) and in all subsequent amendments and post-effective amendments or supplements thereto and in any registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the “Registration Statement”) of NLS Pharmaceutics Ltd., a Swiss company (the “Company”), as an individual to become a director of the Company and to the inclusion of his biographical information in the Registration Statement.
Dated: October 7, 2020
/s/ Stig Løkke Pedersen | |
Stig Løkke Pedersen |